CLIA Grade Multiplex Immunoassays for Immuno-Oncology Drug Development

Immunoassays validated to clinical laboratory standards from patient derived serum and plasma can correlate with what is going on in the tumor micro-environment and answer 3 major challenges in immuno-oncology drug development:

  1. Demonstrate pharmacodynamic effects of treatment
  2. Provide a basis for what type of patients are the best responders
  3. Correlating on-drug effects with  clinical responses:
    • desired = tumor shrinkage, survival, well-being
    • undesired = side effects, adverse events, toxicity

Myriad RBM’s multiplex analysis of several broad groups of cytokines, chemokines and growth factors from blood can profile key aspects of immunotherapy for cancer:

  1. T cell presence and IFNg signaling
  2. Inflammation status
  3. MDSCs  (myeloid derived suppressor cells)
  4. Tumor burden
  5. Angiogenesis

Read the Immunoassay Manufacturing and Lot Management white paper to learn about our reproducible biomarker testing results that are consistent year after year to support clinical trials.

Read the Immunoassay Manufacturing and Lot Management white paper: